HIV, HBV, and HCV Testing in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Experience From a Comprehensive Cancer...

Area of Science:

• Oncology
• Infectious Diseases
• Public Health

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
• HIV, HBV, and HCV infections are risk factors for DLBCL and can complicate treatment.
• DLBCL in HIV-positive individuals is a significant cause of morbidity and mortality.

Purpose of the Study:

• To assess screening rates for HIV, HBV, and HCV in DLBCL patients undergoing systemic therapy.
• To identify factors associated with viral screening in this patient population.

Main Methods:

• Retrospective analysis of 535 newly diagnosed DLBCL patients treated between January 2018 and December 2023.
• Patients were assessed for HBV, HCV, and HIV testing or prior diagnosis within a defined timeframe.
• Statistical analyses included chi-squared, Fisher's exact, and logistic regression models.

Main Results:

• 77% of patients had HBV testing, 51.4% had HIV testing, and 53% had HCV testing.
• Younger patients were more likely to be screened for HIV and HCV.
• No significant association was found between age and HBV testing.

Conclusions:

• Pre-treatment screening rates for HIV, HBV, and HCV in DLBCL patients are suboptimal.
• Interventions are needed to improve viral testing rates.
• Increased screening can reduce treatment-related morbidity and mortality.